News
-
CLINICAL TRIALS | Positive Results Found with Transplant for Patients with Aplastic Anemia
The findings were reported in the journal Blood. The trial’s cohort included 35% of patients from underrepresented racial and/or ethnic groups, suggesting that this BMT method for patients without a…
Read More » -
-
PUBLICATION | Travel Guidance for Patients and Families
Welcome to ‘Travel Guidance for Patients & Families’, on the newest TIF’s publications! This practical handbook is intended specifically for travelers with thalassaemia, sickle cell disease, and rare anaemias. Our…
Read More » -
CALL TO ALL PATIENTS | Your Voice Matters in Research!
Today, we invite you to be an active participant in ensuring that research that takes place is aligned with your specific requirements and challenges. Your firsthand experiences as patients offer…
Read More » -
EHA2023 | Crovalimab Appears Non-inferior to Eculizumab in PNH, Data Shows
At the 2023 EHA Congress, researchers presented data from the ongoing COMMODORE 2 study, which was designed to determine whether crovalimab is non-inferior to eculizumab for multiple clinical endpoints among…
Read More » -
OPINION | Proposed SoHO Legislation Could Transform Blood Sustainability in Europe
In this article, she reflected on the importance of EU’s SoHO Regulation – read TIF’s Position Paper on the Regulation here – proposing updated rules on blood, tissue and cells,…
Read More » -
AWARDS | Health Ministry Honours Mr Panos Englezos, TIF’s President
The Health Ministry of Cyprus honoured the outgoing chairman of the National Thalassaemia Committee and President of the Thalassaemia International Federation (TIF), Mr. Panos Englezos, with a prize-giving ceremony. The…
Read More » -
GENE THERAPY | FDA Decision on Lovo-cel for SCD Now Expected by Year’s End
The regulatory agency has agreed to review an application from lovo-cel’s developer, Bluebird Bio, requesting the gene therapy’s approval for SCD patients ages 12 and older. Moreover, the FDA has given the application priority…
Read More » -
PREGNANCY | Study Results Indicate AIHA in Pregnant Women Is Manageable
Among these patients, however, close monitoring, the administration of therapy when needed, and the awareness of potential complications, both for the mother and fetus, are essential for maximizing the odds…
Read More » -
EHA2023 | MASP-3 Inhibitor Demonstrates Clinical Efficacy in Paroxysmal Nocturnal Hemoglobinuria
OMS906 led to transfusion independence in the majority of patients with PNH enrolled so far on the trial (n = 10). PNH, a rare and life-threatening blood disorder, is characterized…
Read More »